— Know what they know.
Not Investment Advice

AKBA NASDAQ

Akebia Therapeutics, Inc.
1W: -9.7% 1M: -28.2% 3M: -13.6% YTD: -34.2% 1Y: -65.1% 3Y: -2.9% 5Y: -70.4%
$1.02
+0.00 (+0.00%)
 
Weekly Expected Move ±11.9%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 29 · $273.6M mcap · 262M float · 1.38% daily turnover · Short 31% of daily vol

Balance Sheet Trends

Total Assets
$377M +70.6% ▲
5Y CAGR: -10.2%
Total Liabilities
$344M +27.5% ▲
5Y CAGR: -2.8%
Shareholders Equity
$33M +166.3% ▲
5Y CAGR: -33.3%
Cash & Investments
$185M +256.4% ▲
5Y CAGR: -7.2%
Total Debt
$216M +14.6% ▲
5Y CAGR: +11.4%
Net Debt
$31M -77.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$150M$90M$43M$52M$185M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$150M$90M$43M$52M$185M
Net Receivables$52M$40M$39M$34M$47M
Inventory$37M$22M$16M$16M$16M
Other Current Assets$0$33M$20M$7M-$63M
Total Current Assets$271M$185M$118M$114M$185M
Property, Plant & Equip.$41M$34M$16M$10M$0
Goodwill & Intangibles$167M$131M$95M$59M$59M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$50M$5M$12M$37M$133M
Total Non-Current Assets$258M$171M$124M$107M$192M
Total Assets$529M$356M$242M$221M$377M
— Liabilities —
Accounts Payable$34M$18M$15M$15M$21M
Short-Term Debt$98M$32M$20M$4M$40M
Deferred Revenue$21M$4M$0$0$0
Other Current Liabilities$31M$53M$18M$23M$102M
Total Current Liabilities$261M$130M$100M$81M$163M
Long-Term Debt$0$34M$71M$175M$176M
Other Non-Current Liab.$139M$115M$49M$10M$5M
Total Non-Current Liabilities$194M$221M$172M$189M$181M
Total Liabilities$455M$351M$272M$270M$344M
— Equity —
Common Stock$1K$2K$2K$2K$2K
Retained Earnings-$1.5B-$1.6B-$1.6B-$1.7B-$1.7B
Accumulated OCI$6K$6K$6K$6K$6K
Total Stockholders Equity$74M$5M-$31M-$49M$33M
Total Liabilities & Equity$529M$356M$242M$221M$377M
— Key Metrics —
Total Debt$136M$100M$104M$189M$216M
Net Debt-$14M$9M$61M$137M$31M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms